Moreover, time to AML progression in isolated +8 patients with mutations in STAG2, SRSF2 and/or RUNX1 was similar to CK (14 vs. 11.7 months; p > 0.05; Figure S1a) and tended to have a comparable OS to those patients (Figure S1b). This evidence concerns the gene SRSF2 and acute myeloid leukemia.